Table:
Regulators	Target genes	Anti-cancer drugs	Cell or tissue types	Function	Effect	References
HuR	ER	Tamoxifen	Breast cancer cell	mRNA stability ↑	Resistance ↑	[13]
HuR	COX-2	Lapatinib	Breast cancer cell	mRNA stability ↑	Invasion ↑Metastasis ↑	[19]
HuR	TGIF	ATO	Hepatocellular carcinoma cell	mRNA stability ↑	Cell death ↓	[16]
HuR	dCK	Gemcitabine	Pancreatic cancer	Translation ↑	Sensitivity ↑	[17]
HuR	BCL2	Etoposide, Topotecan, Cisplatin	Glioma cell	Translation ↑	Resistance ↑	[21]
HuR	TOP2A	Doxorubicin	Hela cell	Translation ↑	Sensitivity ↑	[25]
HuR	Several targets	Doxorubicin	Breast cancer cell	Translation ↑	Sensitivity ↑	[24]
HuR	Beta-tubulin	Cisplatin	Ovarian cancer cells	Translation ↑	Resistance ↑	[22]
RBM3	Unknown	Cisplatin	Epithelial ovarian cancer	Unknown	Sensitivity ↑	[28]
RBM5	Unknown	Cisplatin	Non-small cell lung cancer	Unknown	Sensitivity ↑	[29]
IMP3	BCRP	Doxorubicin, Mtoxantrone	Breast cancer cell	mRNA stability ↑	Resistance ↑	[30]
CUG-BP1	Survivin	Camptothecin	Oesophageal cancer	mRNA stability ↑	Resistance ↑	[31]
BRF1	cIAP2	Cisplatin	Head and neck squamousCarcinoma cell lines	mRNA degradation	Sensitivity ↑	[33]
HnRNPs H1/H2	TYMP	5′-deoxyfluorouridine	Histiocytic lymphoma cell	Splicing	Resistance ↑	[34]
MTDH	Several targets	Mitomycin C, BIBF1120	Endometrial cancer cell line	Stress granule formation?	Resistance ↑	[38]

Convert the diagram to Markdown syntax.

| Regulators | Target genes | Anti-cancer drugs | Cell or tissue types | Function | Effect | References | 
 | --- | --- | --- | --- | --- | --- | --- | 
 | HuR | ER | Tamoxifen | Breast cancer cell | mRNA stability ↑ | Resistance ↑ | [13] | 
 | HuR | COX-2 | Lapatinib | Breast cancer cell | mRNA stability ↑ | Invasion ↑Metastasis ↑ | [19] | 
 | HuR | TGIF | ATO | Hepatocellular carcinoma cell | mRNA stability ↑ | Cell death ↓ | [16] | 
 | HuR | dCK | Gemcitabine | Pancreatic cancer | Translation ↑ | Sensitivity ↑ | [17] | 
 | HuR | BCL2 | Etoposide, Topotecan, Cisplatin | Glioma cell | Translation ↑ | Resistance ↑ | [21] | 
 | HuR | TOP2A | Doxorubicin | Hela cell | Translation ↑ | Sensitivity ↑ | [25] | 
 | HuR | Several targets | Doxorubicin | Breast cancer cell | Translation ↑ | Sensitivity ↑ | [24] | 
 | HuR | Beta-tubulin | Cisplatin | Ovarian cancer cells | Translation ↑ | Resistance ↑ | [22] | 
 | RBM3 | Unknown | Cisplatin | Epithelial ovarian cancer | Unknown | Sensitivity ↑ | [28] | 
 | RBM5 | Unknown | Cisplatin | Non-small cell lung cancer | Unknown | Sensitivity ↑ | [29] | 
 | IMP3 | BCRP | Doxorubicin, Mtoxantrone | Breast cancer cell | mRNA stability ↑ | Resistance ↑ | [30] | 
 | CUG-BP1 | Survivin | Camptothecin | Oesophageal cancer | mRNA stability ↑ | Resistance ↑ | [31] | 
 | BRF1 | cIAP2 | Cisplatin | Head and neck squamousCarcinoma cell lines | mRNA degradation | Sensitivity ↑ | [33] | 
 | HnRNPs H1/H2 | TYMP | 5′-deoxyfluorouridine | Histiocytic lymphoma cell | Splicing | Resistance ↑ | [34] | 
 | MTDH | Several targets | Mitomycin C, BIBF1120 | Endometrial cancer cell line | Stress granule formation? | Resistance ↑ | [38] |